Siddhivinayak Hirve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Siddhivinayak Hirve has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
Wenqing Zhang
World Health Organization, Global Influenza Programme Geneva Switzerland
9 shared publicationsPallavi Lele
KEM Hospital Research Centre Pune (KEMHRC), Vadu Rural Health Program, India
7 shared publicationsSanjay Juvekar
KEM Hospital Research Center, Pune, India
6 shared publicationsDinesh Mondal
Nutrition and Clinical Services division, International Center for Diarrheal Disease Research Bangladesh, Dhaka, Bangladesh
5 shared publicationsMaria Zambon
Virus Reference Department UK Health Security Agency London UK
5 shared publications- Nawi Ng
School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
5 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (3) , e70195
The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019–2023
Background: From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019 to 2023. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of interventions such as passive immunization, vaccines, and antivirals. Methodology: All RSV sequence data submitted to GISAID by WHO project countries from January 1, 2019, to December 31, 2023, was analyzed to evaluate progress in sequencing, lineage distribution, and RSV fusion (F) protein diversity. Results: From 2019 to 2023, 44,571 RSV sequences were submitted to GISAID, including 61% RSV‐A and 39% RSV‐B, with 34% being whole‐genome sequences. WHO project countries contributed 13,280 sequences (30%), with submissions increasing from 158 in 2020 to 3716 in 2023. Median data submission time improved from 1116 days in 2020 to 206 days in 2023. The dominant lineage detected was A.D .1 (20%) for RSV‐A and B.D.4.1.1 (29%) for RSV‐B. The F protein sequences showed high amino acid conservation: 97% for RSV‐A and 96% for RSV‐B. Conclusion: Substantial progress has been made in RSV genomic sequencing capacities in WHO project countries as seen by the increased submissions and improved timeliness of sequence data. RSV exhibited co‐circulating lineages (RSV‐A and RSV‐B) with low F protein diversity. It is important to sustain and further strengthen RSV sequencing capacities in all WHO regions as part of the ongoing WHO Global Genomic Surveillance strategy.
- 15 March 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (3) , e70195
Open AccessThe Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019–2023
Background: From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019 to 2023. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of interventions such as passive immunization, vaccines, and antivirals. Methodology: All RSV sequence data submitted to GISAID by WHO project countries from January 1, 2019, to December 31, 2023, was analyzed to evaluate progress in sequencing, lineage distribution, and RSV fusion (F) protein diversity. Results: From 2019 to 2023, 44,571 RSV sequences were submitted to GISAID, including 61% RSV‐A and 39% RSV‐B, with 34% being whole‐genome sequences. WHO project countries contributed 13,280 sequences (30%), with submissions increasing from 158 in 2020 to 3716 in 2023. Median data submission time improved from 1116 days in 2020 to 206 days in 2023. The dominant lineage detected was A.D .1 (20%) for RSV‐A and B.D.4.1.1 (29%) for RSV‐B. The F protein sequences showed high amino acid conservation: 97% for RSV‐A and 96% for RSV‐B. Conclusion: Substantial progress has been made in RSV genomic sequencing capacities in WHO project countries as seen by the increased submissions and improved timeliness of sequence data. RSV exhibited co‐circulating lineages (RSV‐A and RSV‐B) with low F protein diversity. It is important to sustain and further strengthen RSV sequencing capacities in all WHO regions as part of the ongoing WHO Global Genomic Surveillance strategy.
- Open Access
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
Burden of Respiratory Syncytial Virus among Filipino Children in Comparison with Influenza and SARS-CoV-2: May 2022 – April 2024
Background: Respiratory syncytial virus (RSV), influenza, and SARS-CoV-2 are major causes of morbidity among children, yet comparative burden estimates remain limited in low- and middle-income countries in the Western Pacific Region. We estimated the burden of RSV relative to influenza and SARS-CoV-2 among children less than 24 months (<25 months) in the Philippines. Methods: We applied the World Health Organization (WHO) tiered disease burden estimation approach to estimate RSV-, influenza-, and SARS-CoV-2-associated hospitalizations from 01-May-2022 to 30-April-2024. Proportions were derived and extrapolated to national hospitalization rates using data from the hospital-based RSV Pilot Surveillance, National Health Insurance Program claims as a proxy for non-sentinel admissions, National Demographic and Health Survey data for risk factor assessment, and national population estimates. Findings: We estimated 50,909 RSV-associated hospitalizations (95% CI: 41,310–61,463; rate: 1,163·8 per 100,000), substantially exceeding the corresponding estimates for influenza and SARS-CoV-2. Infants aged 0–5 months accounted for 53·3% of RSV hospitalizations, with hospitalization rates declining with increasing age. RSV was associated with an estimated 3,244 seasonal ICU admissions (95% CI 1,432–5,050; rate 74·1 per 100,000) and 1,460 in-hospital deaths (0–2,711; 33·3 per 100,000).Interpretation: RSV contributes the highest burden of severe disease among children aged <24 months in the Philippines. Available preventive tools, including maternal RSV vaccines and long-acting monoclonal antibodies, could substantially reduce disease burden in this age group.
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBurden of Respiratory Syncytial Virus among Filipino Children in Comparison with Influenza and SARS-CoV-2: May 2022 – April 2024
Background: Respiratory syncytial virus (RSV), influenza, and SARS-CoV-2 are major causes of morbidity among children, yet comparative burden estimates remain limited in low- and middle-income countries in the Western Pacific Region. We estimated the burden of RSV relative to influenza and SARS-CoV-2 among children less than 24 months (<25 months) in the Philippines. Methods: We applied the World Health Organization (WHO) tiered disease burden estimation approach to estimate RSV-, influenza-, and SARS-CoV-2-associated hospitalizations from 01-May-2022 to 30-April-2024. Proportions were derived and extrapolated to national hospitalization rates using data from the hospital-based RSV Pilot Surveillance, National Health Insurance Program claims as a proxy for non-sentinel admissions, National Demographic and Health Survey data for risk factor assessment, and national population estimates. Findings: We estimated 50,909 RSV-associated hospitalizations (95% CI: 41,310–61,463; rate: 1,163·8 per 100,000), substantially exceeding the corresponding estimates for influenza and SARS-CoV-2. Infants aged 0–5 months accounted for 53·3% of RSV hospitalizations, with hospitalization rates declining with increasing age. RSV was associated with an estimated 3,244 seasonal ICU admissions (95% CI 1,432–5,050; rate 74·1 per 100,000) and 1,460 in-hospital deaths (0–2,711; 33·3 per 100,000).Interpretation: RSV contributes the highest burden of severe disease among children aged <24 months in the Philippines. Available preventive tools, including maternal RSV vaccines and long-acting monoclonal antibodies, could substantially reduce disease burden in this age group.
- Open Access
- 22 August 2025
- Published by Wiley
The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights from 25 Project Countries, 2019-2023
Background: From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019–2024. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of interventions such as passive immunization, vaccines and antivirals. Methodology: All RSV sequence data submitted to GISAID by WHO project countries from 1 January 2019 through 31 December 2023 was analyzed to evaluate progress in sequencing, lineage distribution, and RSV fusion (F) protein diversity . Results: From 2019 through 2023, 45,617 RSV sequences were submitted to GISAID, including 61% RSV-A and 39% RSV-B, with 34% being whole-genome sequences. WHO project countries contributed 13,280 sequences (29%), with submissions increasing from 158 in 2020 to 3,716 in 2023. Median data submission time improved from 1,116 days in 2020 to 206 days in 2023. The dominant lineage detected was A.D.1 (20%) for RSV-A and B.D.4.1.1 (29%) for RSV-B. The F protein sequences showed high amino acid conservation: 97% for RSV-A and 96% for RSV-B. Conclusion: Substantial progress has been made in RSV genomic sequencing capacities in WHO project countries as seen by the increased submissions and improved timeliness of sequence data. RSV exhibited co-circulating lineages (RSV-A and RSV-B) with low F protein diversity. It is important to sustain and further strengthen RSV sequencing capacities in all WHO regions as part of the ongoing WHO Global Genomic Surveillance strategy.
- 22 August 2025
- Published by Wiley
Open AccessThe Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights from 25 Project Countries, 2019-2023
Background: From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019–2024. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of interventions such as passive immunization, vaccines and antivirals. Methodology: All RSV sequence data submitted to GISAID by WHO project countries from 1 January 2019 through 31 December 2023 was analyzed to evaluate progress in sequencing, lineage distribution, and RSV fusion (F) protein diversity . Results: From 2019 through 2023, 45,617 RSV sequences were submitted to GISAID, including 61% RSV-A and 39% RSV-B, with 34% being whole-genome sequences. WHO project countries contributed 13,280 sequences (29%), with submissions increasing from 158 in 2020 to 3,716 in 2023. Median data submission time improved from 1,116 days in 2020 to 206 days in 2023. The dominant lineage detected was A.D.1 (20%) for RSV-A and B.D.4.1.1 (29%) for RSV-B. The F protein sequences showed high amino acid conservation: 97% for RSV-A and 96% for RSV-B. Conclusion: Substantial progress has been made in RSV genomic sequencing capacities in WHO project countries as seen by the increased submissions and improved timeliness of sequence data. RSV exhibited co-circulating lineages (RSV-A and RSV-B) with low F protein diversity. It is important to sustain and further strengthen RSV sequencing capacities in all WHO regions as part of the ongoing WHO Global Genomic Surveillance strategy.
- Open Access
- 18 January 2023
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13073
Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019–2020
Background: External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019–2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV‐A and RSV‐B. This manuscript describes the preparation, distribution, and analysis of the 2019–2020 WHO RSV EQA.Methods: Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in‐house or commercial assays already in use at their laboratories.Results: An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping.Conclusions: The WHO RSV EQA 2019–2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
- 18 January 2023
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13073
Open AccessResults from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019–2020
Background: External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019–2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV‐A and RSV‐B. This manuscript describes the preparation, distribution, and analysis of the 2019–2020 WHO RSV EQA.Methods: Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in‐house or commercial assays already in use at their laboratories.Results: An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping.Conclusions: The WHO RSV EQA 2019–2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
- Open Access
- 30 July 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 671-677
Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016‐17
Background: External quality assessments (EQAs) for the molecular detection of respiratory syncytial virus (RSV) are necessary to ensure the provision of reliable and accurate results. One of the objectives of the pilot of the World Health Organization (WHO) Global RSV Surveillance, 2016‐2017, was to evaluate and standardize RSV molecular tests used by participating countries. This paper describes the first WHO RSV EQA for the molecular detection of RSV.Methods: The WHO implemented the pilot of Global RSV Surveillance based on the WHO Global Influenza Surveillance and Response System (GISRS) from 2016 to 2018 in 14 countries. To ensure standardization of tests, 13 participating laboratories were required to complete a 12 panel RSV EQA prepared and distributed by the Centers for Disease Control and Prevention (CDC), USA. The 14th laboratory joined the pilot late and participated in a separate EQA. Laboratories evaluated a RSV rRT‐PCR assay developed by CDC and compared where applicable, other Laboratory Developed Tests (LDTs) or commercial assays already in use at their laboratories.Results: Laboratories performed well using the CDC RSV rRT‐PCR in comparison with LDTs and commercial assays. Using the CDC assay, 11 of 13 laboratories reported correct results. Two laboratories each reported one false‐positive finding. Of the laboratories using LDTs or commercial assays, results as assessed by Ct values were 100% correct for 1/5 (20%). With corrective actions, all laboratories achieved satisfactory outputs.Conclusions: These findings indicate that reliable results can be expected from this pilot. Continued participation in EQAs for the molecular detection of RSV is recommended.
- 30 July 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 671-677
Open AccessResults from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016‐17
Background: External quality assessments (EQAs) for the molecular detection of respiratory syncytial virus (RSV) are necessary to ensure the provision of reliable and accurate results. One of the objectives of the pilot of the World Health Organization (WHO) Global RSV Surveillance, 2016‐2017, was to evaluate and standardize RSV molecular tests used by participating countries. This paper describes the first WHO RSV EQA for the molecular detection of RSV.Methods: The WHO implemented the pilot of Global RSV Surveillance based on the WHO Global Influenza Surveillance and Response System (GISRS) from 2016 to 2018 in 14 countries. To ensure standardization of tests, 13 participating laboratories were required to complete a 12 panel RSV EQA prepared and distributed by the Centers for Disease Control and Prevention (CDC), USA. The 14th laboratory joined the pilot late and participated in a separate EQA. Laboratories evaluated a RSV rRT‐PCR assay developed by CDC and compared where applicable, other Laboratory Developed Tests (LDTs) or commercial assays already in use at their laboratories.Results: Laboratories performed well using the CDC RSV rRT‐PCR in comparison with LDTs and commercial assays. Using the CDC assay, 11 of 13 laboratories reported correct results. Two laboratories each reported one false‐positive finding. Of the laboratories using LDTs or commercial assays, results as assessed by Ct values were 100% correct for 1/5 (20%). With corrective actions, all laboratories achieved satisfactory outputs.Conclusions: These findings indicate that reliable results can be expected from this pilot. Continued participation in EQAs for the molecular detection of RSV is recommended.
- Open Access
- 12 March 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 638-646
Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance
Background: Human respiratory syncytial virus (RSV) causes illnesses among all age groups and presents a burden to healthcare services. To better understand the epidemiology and seasonality of RSV in different geographical areas, the World Health Organization (WHO) coordinated a pilot initiative to access the feasibility of establishing RSV surveillance using the existing Global Influenza Surveillance and Response System (GISRS) platform.Objectives: To describe and compare RSV and influenza seasonality in countries in the northern andsouthern temperate, and tropics during the period January 2017 to April 2019.Methods: Fourteen countries in six WHO regions participating in the GISRS were invited for the pilot. Hospitalized patients presenting with severe acute respiratory illness (SARI), SARI without fever and outpatients presenting with acute respiratory illness (ARI) were enrolled from January 2017 to April 2019. The expected minimum sample size was 20 samples per week, year‐round, per country. Real‐time RT‐PCR was used to detect RSV and influenza viruses. Results were uploaded to the WHO FluMart platform.Results: Annual seasonality of RSV was observed in all countries, which overlapped to a large extent with the influenza activity. In countries, in temperate regions RSV peaked in the autumn/winter months. In Egypt, a subtropical country, RSV activity peaked in the cooler season. In the tropical regions, RSV peaked during the rainy seasons.Conclusion: Early findings from the WHO RSV surveillance pilot based on the GISRS suggest annual seasonal patterns for of RSV circulation that overlap with influenza. RSV surveillance needs to be continued for several more seasons to establish seasonality patterns to inform prevention and control strategies.
- 12 March 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 638-646
Open AccessHuman respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance
Background: Human respiratory syncytial virus (RSV) causes illnesses among all age groups and presents a burden to healthcare services. To better understand the epidemiology and seasonality of RSV in different geographical areas, the World Health Organization (WHO) coordinated a pilot initiative to access the feasibility of establishing RSV surveillance using the existing Global Influenza Surveillance and Response System (GISRS) platform.Objectives: To describe and compare RSV and influenza seasonality in countries in the northern andsouthern temperate, and tropics during the period January 2017 to April 2019.Methods: Fourteen countries in six WHO regions participating in the GISRS were invited for the pilot. Hospitalized patients presenting with severe acute respiratory illness (SARI), SARI without fever and outpatients presenting with acute respiratory illness (ARI) were enrolled from January 2017 to April 2019. The expected minimum sample size was 20 samples per week, year‐round, per country. Real‐time RT‐PCR was used to detect RSV and influenza viruses. Results were uploaded to the WHO FluMart platform.Results: Annual seasonality of RSV was observed in all countries, which overlapped to a large extent with the influenza activity. In countries, in temperate regions RSV peaked in the autumn/winter months. In Egypt, a subtropical country, RSV activity peaked in the cooler season. In the tropical regions, RSV peaked during the rainy seasons.Conclusion: Early findings from the WHO RSV surveillance pilot based on the GISRS suggest annual seasonal patterns for of RSV circulation that overlap with influenza. RSV surveillance needs to be continued for several more seasons to establish seasonality patterns to inform prevention and control strategies.
- Open Access
- 16 February 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 658-670
Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes
Introduction: Respiratory syncytial virus (RSV) is a major cause of hospital admission for acute lower respiratory tract infection in young children.Objectives: We aimed to identify risk factors for hospitalized RSV disease and its severe outcomes.Methods: We conducted a retrospective cohort study analyzing data of a ICD‐10‐code‐based hospital surveillance for severe acute respiratory infections (SARI). Using univariable and multivariable logistic regression analysis, we assessed age‐group, gender, season, and underlying medical conditions as possible risk factors for RSV and its severe outcomes including ICU admission, application of ventilator support, and death, respectively.Results: Of the 413 552 patients hospitalized with SARI in the database, 8761 were diagnosed with RSV from week 01/2009 to 20/2018 with 97% (8521) aged <5 years. Among children aged <5 years, age‐groups 0‐5 months (OR: 20.29, 95% CI: 18.37‐22.41) and 6 months‐1 year (OR: 4.59, 95% CI: 4.16‐5.06), and underlying respiratory and cardiovascular disorders specific to the perinatal period (OR: 1.32, 95% CI: 1.11‐1.57) were risk factors for being diagnosed with RSV. Age‐group 0‐5 months (OR: 2.39, 95% CI: 1.45‐3.94), low birth weight (OR: 6.77, 95% CI: 1.28‐35.71), preterm newborn (OR: 6.71, 95% CI: 2.19‐20.61), underlying respiratory and cardiovascular disorders specific to the perinatal period (OR: 4.97, 95% CI: 3.36‐7.34), congenital malformation of the heart (OR: 3.65, 95% CI: 1.90‐7.02), congenital malformation of the great vessels (OR: 3.50, 95% CI: 1.10‐11.18), congenital defect originating in perinatal period (OR: 4.07, 95% CI: 1.71‐9.70), cardiovascular disease (OR: 5.19, 95% CI: 2.77‐9.72), neurological disorders (OR: 6.48, 95% CI: 3.76‐11.18), blood disease (OR: 3.67, 95% CI: 1.98‐6.79), and liver disease (OR: 14.99, 95% CI: 1.49‐150.82) contributed to ICU admission in RSV cases.Conclusions: Using ICD‐10‐based surveillance data allows to identify risk factors for hospitalized RSV disease and its severe outcomes, and quantify the risk in different age‐groups.
- 16 February 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 658-670
Open AccessRisk factors for hospitalized respiratory syncytial virus disease and its severe outcomes
Introduction: Respiratory syncytial virus (RSV) is a major cause of hospital admission for acute lower respiratory tract infection in young children.Objectives: We aimed to identify risk factors for hospitalized RSV disease and its severe outcomes.Methods: We conducted a retrospective cohort study analyzing data of a ICD‐10‐code‐based hospital surveillance for severe acute respiratory infections (SARI). Using univariable and multivariable logistic regression analysis, we assessed age‐group, gender, season, and underlying medical conditions as possible risk factors for RSV and its severe outcomes including ICU admission, application of ventilator support, and death, respectively.Results: Of the 413 552 patients hospitalized with SARI in the database, 8761 were diagnosed with RSV from week 01/2009 to 20/2018 with 97% (8521) aged <5 years. Among children aged <5 years, age‐groups 0‐5 months (OR: 20.29, 95% CI: 18.37‐22.41) and 6 months‐1 year (OR: 4.59, 95% CI: 4.16‐5.06), and underlying respiratory and cardiovascular disorders specific to the perinatal period (OR: 1.32, 95% CI: 1.11‐1.57) were risk factors for being diagnosed with RSV. Age‐group 0‐5 months (OR: 2.39, 95% CI: 1.45‐3.94), low birth weight (OR: 6.77, 95% CI: 1.28‐35.71), preterm newborn (OR: 6.71, 95% CI: 2.19‐20.61), underlying respiratory and cardiovascular disorders specific to the perinatal period (OR: 4.97, 95% CI: 3.36‐7.34), congenital malformation of the heart (OR: 3.65, 95% CI: 1.90‐7.02), congenital malformation of the great vessels (OR: 3.50, 95% CI: 1.10‐11.18), congenital defect originating in perinatal period (OR: 4.07, 95% CI: 1.71‐9.70), cardiovascular disease (OR: 5.19, 95% CI: 2.77‐9.72), neurological disorders (OR: 6.48, 95% CI: 3.76‐11.18), blood disease (OR: 3.67, 95% CI: 1.98‐6.79), and liver disease (OR: 14.99, 95% CI: 1.49‐150.82) contributed to ICU admission in RSV cases.Conclusions: Using ICD‐10‐based surveillance data allows to identify risk factors for hospitalized RSV disease and its severe outcomes, and quantify the risk in different age‐groups.
- Open Access
- 31 October 2019
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 647-657
Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot
Background: The lack of a uniform surveillance case definition poses a challenge to characterize the epidemiology, clinical features, and disease burden of the respiratory syncytial virus (RSV). Global standards for RSV surveillance will inform immunization policy when RSV vaccines become available.Methods: The WHO RSV surveillance pilot leverages the capacities of the Global Influenza Surveillance and Response System (GISRS). Hospitalized and non‐hospitalized medically attended patients of any age were tested for RSV using standardized molecular diagnostics throughout the year in fourteen countries. An extended severe acute respiratory infection (extended SARI) or an acute respiratory infection (ARI) case definition was used that did not require fever as a criterion.Results: Amongst 21 221 patients tested for RSV between January 2017 and September 2018, 15 428 (73%) were hospital admissions. Amongst hospitalized RSV‐positive patients, 50% were aged <6 months and 88% <2 years. The percentage of patients testing positive for RSV was 37% in children <6 months and 25% in those aged 6 months to 2 years. Patients with fever were less likely to be RSV positive compared to those without fever (OR 0.74; 95% CI: 0.63‐0.86). For infants <6 months, 29% of RSV ARI cases did not have fever.Conclusion: Requiring fever in a case definition for RSV lowers the sensitivity to detect cases in young children. Countries should consider ways to leverage the GISRS platform to implement RSV surveillance with an augmented case definition amongst the young pediatric population.
- 31 October 2019
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 647-657
Open AccessClinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot
Background: The lack of a uniform surveillance case definition poses a challenge to characterize the epidemiology, clinical features, and disease burden of the respiratory syncytial virus (RSV). Global standards for RSV surveillance will inform immunization policy when RSV vaccines become available.Methods: The WHO RSV surveillance pilot leverages the capacities of the Global Influenza Surveillance and Response System (GISRS). Hospitalized and non‐hospitalized medically attended patients of any age were tested for RSV using standardized molecular diagnostics throughout the year in fourteen countries. An extended severe acute respiratory infection (extended SARI) or an acute respiratory infection (ARI) case definition was used that did not require fever as a criterion.Results: Amongst 21 221 patients tested for RSV between January 2017 and September 2018, 15 428 (73%) were hospital admissions. Amongst hospitalized RSV‐positive patients, 50% were aged <6 months and 88% <2 years. The percentage of patients testing positive for RSV was 37% in children <6 months and 25% in those aged 6 months to 2 years. Patients with fever were less likely to be RSV positive compared to those without fever (OR 0.74; 95% CI: 0.63‐0.86). For infants <6 months, 29% of RSV ARI cases did not have fever.Conclusion: Requiring fever in a case definition for RSV lowers the sensitivity to detect cases in young children. Countries should consider ways to leverage the GISRS platform to implement RSV surveillance with an augmented case definition amongst the young pediatric population.
- Open Access
- 8 October 2019
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 615-621
Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden
The World Health Organization (WHO) recently completed the first phase of a RSV surveillance pilot study in fourteen countries (two to three in each WHO region) building on the Global Influenza Surveillance and Response System (GISRS). This active surveillance strategy had several objectives including understanding RSV‐related health burden in a variety of settings. A range of approaches can be used to estimate disease burden; most approaches could not be applied by participating countries in the WHO surveillance pilot. This article provides the recommendations made by WHO for strengthening and expanding the scope of the RSV surveillance in the next phase to enable burden estimation.
- 8 October 2019
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 615-621
Open AccessApproaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden
The World Health Organization (WHO) recently completed the first phase of a RSV surveillance pilot study in fourteen countries (two to three in each WHO region) building on the Global Influenza Surveillance and Response System (GISRS). This active surveillance strategy had several objectives including understanding RSV‐related health burden in a variety of settings. A range of approaches can be used to estimate disease burden; most approaches could not be applied by participating countries in the WHO surveillance pilot. This article provides the recommendations made by WHO for strengthening and expanding the scope of the RSV surveillance in the next phase to enable burden estimation.
- Open Access
- 24 August 2019
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 622-629
Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance—opportunities and challenges
Background: Respiratory syncytial virus (RSV)‐associated acute lower respiratory infection is a common cause for hospitalization and hospital deaths in young children globally. There is urgent need to generate evidence to inform immunization policies when RSV vaccines become available. The WHO piloted a RSV surveillance strategy that leverages the existing capacities of the Global Influenza Surveillance and Response System (GISRS) to better understand RSV seasonality, high‐risk groups, validate case definitions, and develop laboratory and surveillance standards for RSV.Methods: The RSV sentinel surveillance strategy was piloted in 14 countries. Patients across all age groups presenting to sentinel hospitals and clinics were screened all year‐round using extended severe acute respiratory infection (SARI) and acute respiratory infection (ARI) case definitions for hospital and primary care settings, respectively. Respiratory specimens were tested for RSV at the National Influenza Centre (NIC) using standardized molecular diagnostics that had been validated by an External Quality Assurance program. The WHO FluMart data platform was adapted to receive case‐based RSV data and visualize interactive visualization outputs.Results: Laboratory standards for detecting RSV by RT‐PCR were developed. A review assessed the feasibility and the low incremental costs for RSV surveillance. Several challenges were addressed related to case definitions, sampling strategies, the need to focus surveillance on young children, and the data required for burden estimation.Conclusions: There was no evidence of any significant adverse impact on the functioning of GISRS which is primarily intended for virologic and epidemiological surveillance of influenza.
- 24 August 2019
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 622-629
Open AccessLeveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance—opportunities and challenges
Background: Respiratory syncytial virus (RSV)‐associated acute lower respiratory infection is a common cause for hospitalization and hospital deaths in young children globally. There is urgent need to generate evidence to inform immunization policies when RSV vaccines become available. The WHO piloted a RSV surveillance strategy that leverages the existing capacities of the Global Influenza Surveillance and Response System (GISRS) to better understand RSV seasonality, high‐risk groups, validate case definitions, and develop laboratory and surveillance standards for RSV.Methods: The RSV sentinel surveillance strategy was piloted in 14 countries. Patients across all age groups presenting to sentinel hospitals and clinics were screened all year‐round using extended severe acute respiratory infection (SARI) and acute respiratory infection (ARI) case definitions for hospital and primary care settings, respectively. Respiratory specimens were tested for RSV at the National Influenza Centre (NIC) using standardized molecular diagnostics that had been validated by an External Quality Assurance program. The WHO FluMart data platform was adapted to receive case‐based RSV data and visualize interactive visualization outputs.Results: Laboratory standards for detecting RSV by RT‐PCR were developed. A review assessed the feasibility and the low incremental costs for RSV surveillance. Several challenges were addressed related to case definitions, sampling strategies, the need to focus surveillance on young children, and the data required for burden estimation.Conclusions: There was no evidence of any significant adverse impact on the functioning of GISRS which is primarily intended for virologic and epidemiological surveillance of influenza.